Dr. Bedlack and the 64 ALS Reversals
Original source
Dr. Bedlack and the 64 ALS Reversals (opens in a new tab)Curalysis describes Dr. Richard Bedlack’s Reversal Program, which has identified more than 60 people reported to have sustained functional improvements after an ALS diagnosis. The article says related trials of Lunasin and Theracurmin found the supplements safe but did not slow progression or produce reversals. It also describes an ongoing open-label trial, ROAR-DIGAP, that matches participants to supplements using genetic and biomarker analyses.
Why this matters
The work may help researchers investigate whether reported reversals reflect misdiagnosis, unusual disease biology or treatment effects. However, the article does not establish that any supplement reverses or slows ALS, and the described studies do not change treatment recommendations.
Limitations and context
This account comes from a Curalysis blog post, not a cited peer-reviewed research paper or trial report. The source does not provide enough methodological detail to independently assess the reversal cases, genetic findings or trial results. ROAR-DIGAP is described as open-label and without a placebo control, so any future changes would need careful comparison and independent confirmation.